Advanced gastric cancer
Conditions
Interventions
A:Preoperative chemotherapy of DOX for 4 cycles, capecitabine 1000mg/m2, bid, p.o, 1 to 14 days
oxaliplatin 130mg/m2, ivgtt, 2h, d1, docetaxel 60mg/m2, ivgtt, d1, 21 day/cycle, operation after 2~4 weeks, and postoperative chemotherapy of XP for 4cycles after surgery
B:Preoperative chemotherapy of XP for 4 cycles, capecitabine 1000mg/m2, bid, p.o, 1 to 14 days
oxaliplatin 130mg/m2, ivgtt, 2h, d1, 21 day/cycle, operation after 2~4 weeks, and postoperative chemotherapy of XP for 4cycles after surgery
C:Operation after 2~4 weeks, and postoperative chemotherapy of XP for 8cycles after surgery, capecitabine 1000mg/m2, bid p.o, 1 to 14 days
oxaliplatin 130mg/m2, ivgtt, 2h, d1
Sponsors
Hebei Medical University affiliated Fourth Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Endoscopy, CT and other tests determined to be in advanced gastric cancer; 2. Biopsy diagnosed as gastric adenocarcinoma; 3. All patients required EUS, CT (or PET-CT) and laparoscopic staging assessment before treatment, according to the 7th edition AJCC, staging III; 4. Patients with MDT consultation identified as potentially resectable cases, with no procedure-related contraindications, expected to surgical resection; 5. Karnofsky score more than 80, ECOG score 0-1; 6. Expected survival longer than 6 months; 7. Male and female aged 20 to 60 years old; 8. According to RECIST 1.1: have measurable disease; 9. signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with kidney dysfunction accompanied, cardiovascular system and other serious diseases, affecting chemotherapy or surgery; 2.Allergy with capecitabine, oxaliplatin, docetaxel and excipients; 3. Received any form of chemotherapy or other investigational drug before enrolled; 4. Patients in child-bearing period are not willing to take contraceptive measures; women with pregnancy and lactation; 5. Patients associated with dysphagia, active peptic ulcer, incompleteness intestinal obstruction, active gastrointestinal bleeding, perforation caused difficulties oral for apecitabine; 6. Patients with other tumors combined.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathological complete response rate(PCR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR);R0-resection rate;3-years Disease-free survival(DFS);3-years over survival rate;Safety; | — |
Countries
China
Contacts
Public ContactQun Zhao
Outcome results
None listed